var data={"title":"Dextroamphetamine and amphetamine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dextroamphetamine and amphetamine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6006?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dextroamphetamine-and-amphetamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dextroamphetamine and amphetamine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=dextroamphetamine-and-amphetamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dextroamphetamine and amphetamine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708680\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Abuse potential (Adderall, Adderall XR, Mydayis):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">CNS stimulants, including amphetamine-containing products, have a high potential for abuse and dependence. Administration of amphetamines for prolonged periods of time may lead to drug dependence and must be avoided. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular events (Adderall, Adderall XR):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Misuse of amphetamines may cause sudden death and serious cardiovascular adverse events.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158728\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adderall;</li>\n      <li>Adderall XR;</li>\n      <li>Mydayis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F935382\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Adderall XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158745\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Central Nervous System Stimulant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158731\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Use lowest effective individualized dose; administer first dose as soon as awake.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ADHD:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note</b>: Interrupt therapy occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> Initial: 5 mg once or twice daily; may increase daily dose in 5 mg increments at weekly intervals until optimal response is obtained; usual dosage range: 5 to 40 mg/day in 1 to 3 divided doses. <b>Note</b>: Although doses greater than 40 mg/day will rarely be necessary, doses as high as 60 mg/day have been shown to be safe and effective (Spencer 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adderall XR: Initial: 20 mg once daily in the morning; higher doses (up to 60 mg/day) have been evaluated; however, there is not adequate evidence that higher doses afforded additional benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from immediate release to Adderall XR: </i>Switch to Adderall XR at the same total daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mydayis: Initial: 12.5 mg to 25 mg once daily in the morning; may increase daily dose by 12.5 mg no sooner than once weekly; maximum: 50 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from other dextroamphetamine and amphetamine formulations to Mydayis: </i>Discontinue previous formulation and titrate using above schedule; do not substitute on a mg-per-mg basis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Narcolepsy:</b> <i>Immediate release</i>: Oral: Initial: 10 mg once daily in the morning; may increase daily dose in 10 mg increments at weekly intervals until optimal response is obtained; usual dosage range: 5 to 60 mg/day in 1 to 3 divided doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158738\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dextroamphetamine-and-amphetamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dextroamphetamine and amphetamine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Use lowest effective individualized dose; administer first dose as soon as awake.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ADHD:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note</b>: Interrupt therapy occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;3 years: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 3 to 5 years: Immediate release: Initial 2.5 mg once daily in the morning; may increase daily dose in 2.5 mg increments at weekly intervals until optimal response is obtained; usual dosage range: 2.5 to 40 mg/day in 1 to 3 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Immediate release:</i> Initial: 5 mg once or twice daily; may increase daily dose in 5 mg increments at weekly intervals until optimal response is obtained; usual dosage range: 5 to 40 mg/day in 1 to 3 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended release: </i>Adderall XR: 5 to 10 mg once daily in the morning; may increase daily dose in 5 to 10 mg increments at weekly intervals until optimal response is obtained; maximum: 30 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from immediate release to Adderall XR: </i>Switch to Adderall XR at the same total daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Immediate release:</i> Initial: 5 mg once or twice daily; may increase daily dose in 5 mg increments at weekly intervals until optimal response is obtained; usual dosage range: 5 to 40 mg/day in 1 to 3 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended release: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adderall XR: Initial: 10 mg once daily in the morning; may increase to 20 mg daily after 1 week if needed; higher doses (up to 60 mg/day) have been evaluated; however, there is not adequate evidence that higher doses afforded additional benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from immediate release to Adderall XR: </i>Switch to Adderall XR at the same total daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mydayis: Initial: 12.5 mg once daily in the morning; may increase daily dose by 12.5 mg no sooner than weekly; maximum: 25 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from other dextroamphetamine and amphetamine formulations to Mydayis: </i>Discontinue previous formulation and titrate using above schedule; do not substitute on a mg-per-mg basis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Narcolepsy:</b> <i>Immediate release</i>: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 years: Initial: 5 mg daily; may increase daily dose in 5 mg increments at weekly intervals until optimal response is obtained; usual dosage: 5 to 60 mg/day in 1 to 3 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158732\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; use with caution and start at low end of dosage range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22890418\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release and Adderall XR extended release: There are no dosage adjustments provided in the manufacturer's labeling; use with caution; the potential exists for elimination of amphetamine to be inhibited resulting in prolonged exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: There are no specific dosage adjustments provided in the manufacturer's labeling; dextroamphetamine is not dialyzable (Ermer 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mydayis:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (GFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: Maximum dose: 25 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Maximum dose: 12.5 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD (GFR &lt;15 mL/minute/1.73 m<sup>2</sup>): Use is not recommended; dextroamphetamine is not dialyzable</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22890419\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158705\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, extended release, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adderall XR:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 mg [dextroamphetamine sulfate 1.25 mg, dextroamphetamine saccharate 1.25 mg, amphetamine aspartate monohydrate 1.25 mg, amphetamine sulfate 1.25 mg (equivalent to amphetamine base 3.1 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10 mg [dextroamphetamine sulfate 2.5 mg, dextroamphetamine saccharate 2.5 mg, amphetamine aspartate monohydrate 2.5 mg, amphetamine sulfate 2.5 mg (equivalent to amphetamine base 6.3 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">15 mg [dextroamphetamine sulfate 3.75 mg, dextroamphetamine saccharate 3.75 mg, amphetamine aspartate monohydrate 3.75 mg, amphetamine sulfate 3.75 mg (equivalent to amphetamine base 9.4 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">20 mg [dextroamphetamine sulfate 5 mg, dextroamphetamine saccharate 5 mg, amphetamine aspartate monohydrate 5 mg, amphetamine sulfate 5 mg (equivalent to amphetamine base 12.5 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">25 mg [dextroamphetamine sulfate 6.25 mg, dextroamphetamine saccharate 6.25 mg, amphetamine aspartate monohydrate 6.25 mg, amphetamine sulfate 6.25 mg (equivalent to amphetamine base 15.6 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">30 mg [dextroamphetamine sulfate 7.5 mg, dextroamphetamine saccharate 7.5 mg, amphetamine aspartate monohydrate 7.5 mg, amphetamine sulfate 7.5 mg (equivalent to amphetamine base 18.8 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mydayis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">12.5 mg [dextroamphetamine sulfate 3.125 mg, dextroamphetamine saccharate 3.125 mg, amphetamine aspartate monohydrate 3.125 mg, amphetamine sulfate 3.125 mg (equivalent to amphetamine base 7.8 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">25 mg [dextroamphetamine sulfate 6.25 mg, dextroamphetamine saccharate 6.25 mg, amphetamine aspartate monohydrate 6.25 mg, amphetamine sulfate 6.25 mg (equivalent to amphetamine base 15.6 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">37.5 mg [dextroamphetamine sulfate 9.375 mg, dextroamphetamine saccharate 9.375 mg, amphetamine aspartate monohydrate 9.375 mg, amphetamine sulfate 9.375 mg (equivalent to amphetamine base 23.5 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50 mg [dextroamphetamine sulfate 12.5 mg, dextroamphetamine saccharate 12.5 mg, amphetamine aspartate monohydrate 12.5 mg, amphetamine sulfate 12.5 mg (equivalent to amphetamine base 31.3 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 mg [dextroamphetamine sulfate 1.25 mg, dextroamphetamine saccharate 1.25 mg, amphetamine aspartate monohydrate 1.25 mg, amphetamine sulfate 1.25 mg (equivalent to amphetamine base 3.1 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10 mg [dextroamphetamine sulfate 2.5 mg, dextroamphetamine saccharate 2.5 mg, amphetamine aspartate monohydrate 2.5 mg, amphetamine sulfate 2.5 mg (equivalent to amphetamine base 6.3 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">15 mg [dextroamphetamine sulfate 3.75 mg, dextroamphetamine saccharate 3.75 mg, amphetamine aspartate monohydrate 3.75 mg, amphetamine sulfate 3.75 mg (equivalent to amphetamine base 9.4 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">20 mg [dextroamphetamine sulfate 5 mg, dextroamphetamine saccharate 5 mg, amphetamine aspartate monohydrate 5 mg, amphetamine sulfate 5 mg (equivalent to amphetamine base 12.5 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">25 mg [dextroamphetamine sulfate 6.25 mg, dextroamphetamine saccharate 6.25 mg, amphetamine aspartate monohydrate 6.25 mg, amphetamine sulfate 6.25 mg (equivalent to amphetamine base 15.6 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">30 mg [dextroamphetamine sulfate 7.5 mg, dextroamphetamine saccharate 7.5 mg, amphetamine aspartate monohydrate 7.5 mg, amphetamine sulfate 7.5 mg (equivalent to amphetamine base 18.8 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adderall:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 mg [dextroamphetamine sulfate 1.25 mg, dextroamphetamine saccharate 1.25 mg, amphetamine aspartate monohydrate 1.25 mg, amphetamine sulfate 1.25 mg (equivalent to amphetamine base 3.13 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7.5 mg [dextroamphetamine sulfate 1.875 mg, dextroamphetamine saccharate 1.875 mg, amphetamine aspartate monohydrate 1.875 mg, amphetamine sulfate 1.875 mg (equivalent to amphetamine base 4.7 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10 mg [dextroamphetamine sulfate 2.5 mg, dextroamphetamine saccharate 2.5 mg, amphetamine aspartate monohydrate 2.5 mg, amphetamine sulfate 2.5 mg (equivalent to amphetamine base 6.3 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">12.5 mg [dextroamphetamine sulfate 3.125 mg, dextroamphetamine saccharate 3.125 mg, amphetamine aspartate monohydrate 3.125 mg, amphetamine sulfate 3.125 mg (equivalent to amphetamine base 7.8 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">15 mg [dextroamphetamine sulfate 3.75 mg, dextroamphetamine saccharate 3.75 mg, amphetamine aspartate monohydrate 3.75 mg, amphetamine sulfate 3.75 mg (equivalent to amphetamine base 9.4 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">20 mg [dextroamphetamine sulfate 5 mg, dextroamphetamine saccharate 5 mg, amphetamine aspartate monohydrate 5 mg, amphetamine sulfate 5 mg (equivalent to amphetamine base 12.6 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">30 mg [dextroamphetamine sulfate 7.5 mg, dextroamphetamine saccharate 7.5 mg, amphetamine aspartate monohydrate 7.5 mg, amphetamine sulfate 7.5 mg (equivalent to amphetamine base 18.8 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 mg [dextroamphetamine sulfate 1.25 mg, dextroamphetamine saccharate 1.25 mg, amphetamine aspartate monohydrate 1.25 mg, amphetamine sulfate 1.25 mg (equivalent to amphetamine base 3.13 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7.5 mg [dextroamphetamine sulfate 1.875 mg, dextroamphetamine saccharate 1.875 mg, amphetamine aspartate monohydrate 1.875 mg, amphetamine sulfate 1.875 mg (equivalent to amphetamine base 4.7 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10 mg [dextroamphetamine sulfate 2.5 mg, dextroamphetamine saccharate 2.5 mg, amphetamine aspartate monohydrate 2.5 mg, amphetamine sulfate 2.5 mg (equivalent to amphetamine base 6.3 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">12.5 mg [dextroamphetamine sulfate 3.125 mg, dextroamphetamine saccharate 3.125 mg, amphetamine aspartate monohydrate 3.125 mg, amphetamine sulfate 3.125 mg (equivalent to amphetamine base 7.8 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">15 mg [dextroamphetamine sulfate 3.75 mg, dextroamphetamine saccharate 3.75 mg, amphetamine aspartate monohydrate 3.75 mg, amphetamine sulfate 3.75 mg (equivalent to amphetamine base 9.4 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">20 mg [dextroamphetamine sulfate 5 mg, dextroamphetamine saccharate 5 mg, amphetamine aspartate monohydrate 5 mg, amphetamine sulfate 5 mg (equivalent to amphetamine base 12.6 mg)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">30 mg [dextroamphetamine sulfate 7.5 mg, dextroamphetamine saccharate 7.5 mg, amphetamine aspartate monohydrate 7.5 mg, amphetamine sulfate 7.5 mg (equivalent to amphetamine base 18.8 mg)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158688\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158747\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874428\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adderall: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM467750.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274giUXNxxkCbow86Y8zk9LY2Zg==&amp;TOPIC_ID=8723\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM467750.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adderall XR: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021303s032lbl.pdf#page=15&amp;token=icF6Pqa2/gYMkkFB5v4zTfJ1QiqdcUOVavfoFx5eOL6KXEl2NaHx689KjNg3ffM6R9sMdrdMstAu/YV7yaZ1KHQIDMdOTgp9MQMSfcieXLOOQE+K1D61HEMUhi2FY9Bg&amp;TOPIC_ID=8723\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021303s032lbl.pdf#page=15</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mydayis: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022063s000lbl.pdf#page=22&amp;token=rd38vxqSlf/zuf733AYqNbmhqEHWeg/PE127aQeSz4gNCCBhqRmiFKk/DzeOyQ90kkTPvOn+eO15kGPg1Vhh2GszQhJc2CTfbVEQMHgPWtwJfU8NsskQmJvCeyEt6blc&amp;TOPIC_ID=8723\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022063s000lbl.pdf#page=22</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158707\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with or without food. Administer Mydayis consistently either with food or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Administer in 1 to 3 divided doses per day with intervals of 4 to 6 hours between doses. To avoid insomnia, late evening doses should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: To avoid insomnia, afternoon doses should be avoided. Capsule may be swallowed whole or it may be opened and the contents sprinkled on applesauce. Applesauce should be consumed immediately without chewing. Do not divide the contents of the capsule. Do not take less than one capsule per day; a single capsule should not be divided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158706\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Attention-deficit/hyperactivity disorder:</b> Treatment of attention-deficit/hyperactivity disorder (ADHD) as part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Narcolepsy (immediate release only): </b> Treatment of narcolepsy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158753\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Adderall may be confused with Adderall XR, Inderal</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158695\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Systolic hypertension (extended release; adolescents: 12% to 35%; dose related; transient), tachycardia (extended release; adults: &le;6%), palpitations (extended release: 2% to 4%), increased blood pressure, myocardial infarction, Raynaud's phenomenon</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Insomnia (extended release: 8% to 31%), headache (extended release; adults: &le;26%), emotional lability (extended release: 2% to 9%), anxiety (extended release; adults: 7% to 8%), agitation (extended release; adults: 2% to &le;8%), dizziness (extended release: 2% to 7%), irritability (6%), fatigue (extended release: 2% to 6%), drowsiness (extended release: 2% to 4%), speech disturbance (extended release: 2% to 4%), twitching (extended release: 2% to 4%), depression (3%), jitteriness (2%), aggressive behavior, dysphoria, euphoria, exacerbation of vocal tics, formication, outbursts of anger, overstimulation, paresthesia, psychosis, restlessness, talkativeness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis (extended release: 2% to 4%), skin photosensitivity (extended release: 2% to 4%), alopecia, dermatillomania, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Weight loss (extended release: 4% to 10%), decreased libido (extended release: 2% to 4%), dysmenorrhea (extended release: 2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Decreased appetite (extended release: 22% to 36%), xerostomia (extended release: 2% to 35%), abdominal pain (extended release: 11% to 14%), nausea (extended release: 2% to 8%), vomiting (extended release: 2% to 7%), diarrhea (extended release: 2% to 6%), constipation (extended release: 2% to 4%), dyspepsia (extended release: 2% to 4%), teeth clenching (extended release: &le;4%), tooth infection (extended release: &le;4%), anorexia (extended release: 2%), bruxism (2%), unpleasant taste</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary tract infection (extended release: 5%), upper abdominal pain (adolescents: 4%), impotence (extended release: 2% to 4%), erectile dysfunction (2%), frequent erections, prolonged erections</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection (extended release: 2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Dyskinesia, rhabdomyolysis, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, mydriasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea (extended release: 2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (extended release: 5%), accidental injury (children and adolescents: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cardiomyopathy, cerebrovascular accident, exacerbation of Gilles de la Tourette's syndrome, exacerbation of vocal tics, peripheral vascular disease, seizure, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158710\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, angioedema, anaphylaxis) or idiosyncrasy to amphetamine, sympathomimetic amines or any component of the formulation; during or within 14 days following MAOI (including linezolid or methylene blue).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for amphetamines is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release, Adderall XR: Additional contraindications: Advanced arteriosclerosis; symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism; glaucoma, agitated states; history of drug abuse.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158692\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: <b>[US Boxed Warning]: Use has been associated with serious cardiovascular events including sudden death in patients with preexisting structural cardiac abnormalities or other serious heart problems (sudden death in children and adolescents; sudden death, stroke, and MI in adults).</b> These products should be avoided in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could increase the risk of sudden death. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. Patients who develop exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during treatment should undergo a prompt cardiac evaluation. CNS stimulants may increase heart rate (mean increase: 3 to 6 bpm) and blood pressure (mean increase: 2 to 4 mm Hg). Use with caution in patients with cardiovascular conditions that may be exacerbated by increases in blood pressure or heart rate (eg, hypertension, heart failure, recent MI, ventricular arrhythmia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, and urticaria, have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vasculopathy: Stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs/symptoms are usually mild and intermittent, and generally improve with dose reduction or discontinuation. Digital ulceration and/or soft tissue breakdown have been observed rarely; monitor for digital changes during therapy and seek further evaluation (eg, rheumatology) if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) may occur when dextroamphetamine/amphetamine is used in combination with other serotonergic agents (eg, SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, St. John's wort, tryptophan), agents that impair metabolism of serotonin (eg, MAOIs) or CYP2D6 inhibitors that impair metabolism of dextroamphetamine/amphetamine. Concomitant use with MAOIs is contraindicated. If concomitant use of dextroamphetamine/amphetamine with serotonergic drugs or CYP2D6 inhibitors is indicated, initiate dextroamphetamine/amphetamine at a low dose and monitor patient closely for signs and symptoms of SS. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual disturbance: Difficulty in accommodation and blurred vision has been reported with the use of stimulants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; elimination is reduced.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disorders: Use with caution in patients with preexisting psychosis or bipolar disorder. May exacerbate symptoms of behavior and thought disorder in psychotic patients; new onset psychosis or mania may occur with stimulant use; consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, mania) occur. May be associated with aggressive behavior or hostility (causal relationship not established); monitor for development or worsening of these behaviors. Screen patients with comorbid depressive symptoms prior to initiating treatment to determine if they are at risk for bipolar disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; elimination is reduced.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Limited information exists regarding amphetamine use in seizure disorder (Cortese 2013). The manufacturer recommends use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity. If seizures occur, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tourette syndrome/tics: Use with caution in patients with Tourette syndrome or other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation (AACAP [Murphy 2013; Pliszka 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use caution in this age group due to CNS stimulant adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Appetite suppression may occur; particularly in children. Use of stimulants has been associated with weight loss and slowing growth rate; monitor growth rate and weight during treatment. Treatment interruption may be necessary in patients who are not increasing in height or gaining weight as expected. Pediatric patients 12 years and younger experienced high plasma exposure to Mydayis and more adverse reactions, including insomnia and decreased appetite, compared to patients 13 years and older.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion: <b>[US Boxed Warning]: Has high potential for abuse and dependence.</b> <b>Administration for prolonged periods may lead to drug dependence and must be avoided.</b> <b>Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy. </b>Use with caution in patients with history of ethanol or drug abuse. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention-deficit disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Mydayis: Medication errors, including substitution and dispensing errors, may occur, leading to possible overdosage. Do not substitute Mydayis for other amphetamine products on a mg-per-mg basis because of different amphetamine base compositions and differing pharmacokinetic profiles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Abrupt discontinuation following high doses or for prolonged periods may result in symptoms for withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158739\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158697\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8723&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alkalinizing Agents: May decrease the excretion of Amphetamines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the excretion of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihypertensive Agents: Amphetamines may diminish the antihypertensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: May diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May decrease the serum concentration of Amphetamines. More specifically, the ascorbic acid (vitamin C) in many multivitamins may decrease amphetamine concentrations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Amphetamines. Specifically, vitamin C may impair absorption of amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Amphetamines may enhance the analgesic effect of Opioid Analgesics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May increase the absorption of Amphetamine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinary Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158723\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Amphetamine serum levels may be reduced if taken with acidic food, juices, or vitamin C. Management: Monitor response when taken concurrently.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158700\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158713\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Refer to individual monographs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15041845\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Amphetamines are present in breast milk. The manufacturer recommends that mothers taking dextroamphetamine/amphetamine refrain from breastfeeding. Refer to individual monographs</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158702\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiac evaluation should be completed on any patient who develops exertional chest pain, unexplained syncope, and any symptom of cardiac disease during treatment with stimulants; behavioral changes; CNS activity; height, weight and growth parameters in children; signs of peripheral vasculopathy (eg, digital changes). Assess for risk of abuse prior to prescribing and signs of misuse, abuse, or addiction throughout treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When used for the treatment of ADHD, perform a targeted cardiac history (eg, patient history of previously detected cardiac disease, palpitations, syncope, or seizures; family history of sudden death in children or young adults; hypertrophic cardiomyopathy; long QT syndrome) and physician examination including cardiac examination. Monitor heart rate and blood pressure (baseline; follow-up within 1 to 3 months and routinely at 6 to 12 month intervals thereafter unless clinically indicated with dose titration and weaning of therapy) Consider obtaining ECG prior to initiation (Perrin 2008; Vetter 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158691\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Amphetamines are noncatecholamine, sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals.  A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158709\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> The immediate-release tablets and ER capsules contain d-amphetamine and l-amphetamine salts in the ratio of 3:1.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: Immediate-release tablet: 4 to 6 hours (Dopheide 2009); Adderall XR: 8 to 12 hours (Jain 2017); Mydayis: &le;16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Extended release: Food does not affect absorption, but prolongs T<sub>max</sub> of Adderall XR by 2 to 3 hours and Mydayis by 4 to 5 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 6 to 12 years: d-amphetamine: 9 hours; l-amphetamine: 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents 13 to 17 years: d-amphetamine: 11 hours; l-amphetamine: 13 to 14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: d-amphetamine: 10 hours; l-amphetamine: 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic oxidation via cytochrome P450 to 4-hydroxyamphetamine (active) norephedrine (active), and alpha-hydroxy-amphetamine with both active metabolites subsequently oxidized to 4-hydroxy-norephedrine. Cytochrome P450 2D6 is primarily responsible for the formation of 4-hydroxy-amphetamine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Immediate release: 3 hours; Adderall XR: 7 hours; Mydayis: 7 to 10 hours (children), 8 hours (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (highly dependent on urinary pH); excreted as unchanged amphetamine (30% to 40%, may range from ~1% in alkaline urine to ~75% in acidic urine), and derivatives of alpha-hydroxyamphetamine (50%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5989309\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Adderall XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $854.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $854.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $854.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $854.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $854.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $854.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Amphetamine-Dextroamphet ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $613.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $613.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $613.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $613.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $613.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $613.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Mydayis Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $1,082.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $1,082.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mg (100): $1,082.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $1,082.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Adderall Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $733.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (100): $733.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $733.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $733.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $733.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $733.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $733.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Amphetamine-Dextroamphetamine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $171.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (100): $171.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $171.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $171.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $171.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $171.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $171.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adderall (dextroamphetamine/amphetamine) [prescribing information]. Horsham, PA: Teva Pharmaceuticals; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adderall XR (dextroamphetamine/amphetamine) [prescribing information]. Lexington, MA: Shire US Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee Opinion: No. 479, &ldquo;Methamphetamine Abuse in Women of Reproductive Age,&rdquo; <i>Obstet Gynecol</i>, 2011, 117(3):751-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/21343793/pubmed\" target=\"_blank\" id=\"21343793\">21343793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi: 10.1002/cpt.377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortese S, Holtmann M, Banaschewski T, et al; European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medication in children and adolescents. <i>J Child Psychol Psychiatry</i>. 2013;54(3): 227-246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/23294014/pubmed\" target=\"_blank\" id=\"23294014\">23294014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. <i>Pharmacotherapy</i>. 2009;29(6):656-679.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/19476419/pubmed\" target=\"_blank\" id=\"19476419\">19476419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26926668\"></a>Ermer J, Corcoran M, Lasseter K, Marbury T, Yan B, Martin PT. A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function. <i>Ther Drug Monit</i>. 2016;38(4):546-555.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/26926668/pubmed\" target=\"_blank\" id=\"26926668\">26926668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. <i>Int J Psychiatry Med.</i> 2014;48(3):185-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/25492713/pubmed\" target=\"_blank\" id=\"25492713\">25492713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golub M, Costa L, Crofton K, et al, &quot;NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine,&quot; <i>Birth Defects Res B Dev Reprod Toxicol</i>, 2005, 74(6):471-584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/16167346/pubmed\" target=\"_blank\" id=\"16167346\">16167346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilett KF, Hackett LP, Kristensen JH, Kohan R. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. <i>Br J Clin Pharmacol</i>. 2007;63(3):371-375.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/17380592/pubmed\" target=\"_blank\" id=\"17380592\">17380592</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women [published correction appears in <i>N Engl J Med</i>. 2000;343(18):1348]. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jain R, Jain S, Montano B. Addressing diagnosis and treatment gaps in adults with attention-deficit/hyperactivity disorder. <i>Prim Care Companion CNS Disord </i>2017; 19(5).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/28906602/pubmed\" target=\"_blank\" id=\"28906602\">28906602</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LaGasse LL, Derauf C, Smith LM, et al. Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. <i>Pediatrics</i>. 2012;129(4):681-688.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/22430455/pubmed\" target=\"_blank\" id=\"22430455\">22430455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy TK, Lewin AB, Storch EA, et al. Practice Parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry.</i> 2013;52(12):1341-1359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/24290467/pubmed\" target=\"_blank\" id=\"24290467\">24290467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mydayis (dextroamphetamine/amphetamine) [prescribing information]. Lexington, MA: Shire US Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. <i>Pediatrics</i>. 2008;122(2):451-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/18676566/pubmed\" target=\"_blank\" id=\"18676566\">18676566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007; 46(7): 894-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder.<i> Archives of General Psychiatry</i>. 2001;58(8): 775-782.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/11483144/pubmed\" target=\"_blank\" id=\"11483144\">11483144</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steiner E, Vill&eacute;n T, Hallberg M, et al, &quot;Amphetamine Secretion in Breast Milk,&quot; <i>Eur J Clin Pharmacol</i>, 1984, 27(1):123-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/6489423/pubmed\" target=\"_blank\" id=\"6489423\">6489423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8723 Version 155.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708680\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F158728\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F935382\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F158745\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F158731\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F158738\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F158732\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22890418\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22890419\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F158705\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F158688\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F158747\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874428\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F158707\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F158706\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F158753\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F158695\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F158710\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F158692\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F158739\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F158697\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F158723\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F158700\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F158713\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15041845\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F158702\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F158691\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F158709\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5989309\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8723|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dextroamphetamine-and-amphetamine-patient-drug-information\" class=\"drug drug_patient\">Dextroamphetamine and amphetamine: Patient drug information</a></li><li><a href=\"topic.htm?path=dextroamphetamine-and-amphetamine-pediatric-drug-information\" class=\"drug drug_pediatric\">Dextroamphetamine and amphetamine: Pediatric drug information</a></li></ul></div></div>","javascript":null}